A Phase 2 Study of PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 2 Study of PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2018

At a glance

  • Drugs PCM 075 (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms UNITE
  • Sponsors TrovaGene
  • Most Recent Events

    • 09 Jul 2018 According to a TrovaGene media release, the company is planning complete enrolment and cycle 1 of treatment of the 3 safety lead-in patients in the 2H 2018. The company also anticipates topline preliminary safety and efficacy data of patients treated through the end of 2018 by 2H 2018.
    • 21 Jun 2018 According to a TrovaGene media release, the company has received Institutional Review Board (IRB) approval from Dana-Farber/Harvard Cancer Center and the trial is officially activated and recruiting patients.
    • 21 Jun 2018 According to a TrovaGene media release, David Einstein, MD, Genitourinary Oncology Program at BIDMC, is the principal investigator for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top